Opus Genetics, Inc. Financing Cash Flow
Opus Genetics, Inc. (IRD) reported Financing Cash Flow of $68.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Opus Genetics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $40.90M, a 4414.68% increase year-over-year.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $27.59M, a 34.84% increase year-over-year.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $24.11M.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.54M, a 1186.97% increase year-over-year.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $50.02M, a 1095.01% increase from fiscal 2024.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $4.19M, a 53.38% decline from fiscal 2023.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.98M, a 137.16% increase from fiscal 2022.
- Opus Genetics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $3.79M, a 86.29% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed | Net Cash Provided by (Used in) Financing Activities 132 month | Net Cash Provided by (Used in) Financing Activities 135 month | Net Cash Provided by (Used in) Financing Activities 138 month | Net Cash Provided by (Used in) Financing Activities 141 month | Net Cash Provided by (Used in) Financing Activities 144 month | Net Cash Provided by (Used in) Financing Activities 147 month | Net Cash Provided by (Used in) Financing Activities 150 month | Net Cash Provided by (Used in) Financing Activities 153 month | Net Cash Provided by (Used in) Financing Activities 156 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $40.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $68.50M 10-Q · filed 2026-08-06 | $92.61M derived: sum of 3 quarters · filed 2026-08-06 | $97.15M derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2026-03-31 | $27.59M 10-Q · filed 2026-05-12 | $51.70M derived: sum of 2 quarters · filed 2026-05-12 | $56.25M derived: sum of 3 quarters · filed 2026-05-12 | $57.15M derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2025-12-31 | $24.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $28.65M derived: sum of 2 quarters · filed 2026-03-12 | $29.56M derived: sum of 3 quarters · filed 2026-08-06 | $50.02M 10-K · filed 2026-03-12 | ||||||||||
| 2025-09-30 | $4.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.45M derived: sum of 2 quarters · filed 2026-08-06 | $25.91M 10-Q · filed 2025-11-12 | $25.83M derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2025-06-30 | $906.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $21.37M 10-Q · filed 2026-08-06 | $21.29M derived: sum of 3 quarters · filed 2026-08-06 | $21.64M derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2025-03-31 | $20.46M 10-Q · filed 2026-05-12 | $20.38M derived: sum of 2 quarters · filed 2026-05-12 | $20.73M derived: sum of 3 quarters · filed 2026-05-12 | $22.27M derived: sum of 4 quarters · filed 2026-05-12 | ||||||||||
| 2024-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $270.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.81M derived: sum of 3 quarters · filed 2026-03-12 | $4.19M 10-K · filed 2026-03-12 | ||||||||||
| 2024-09-30 | $353.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.89M derived: sum of 2 quarters · filed 2025-11-12 | $4.27M 10-Q · filed 2025-11-12 | $7.87M derived: sum of 4 quarters · filed 2025-11-12 | ||||||||||
| 2024-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.92M 10-Q · filed 2025-08-13 | $7.52M derived: sum of 3 quarters · filed 2025-08-13 | $12.89M derived: sum of 4 quarters · filed 2025-08-13 | ||||||||||
| 2024-03-31 | $2.38M 10-Q · filed 2025-05-15 | $5.98M derived: sum of 2 quarters · filed 2025-05-15 | $11.36M derived: sum of 3 quarters · filed 2025-05-15 | $11.36M derived: sum of 4 quarters · filed 2025-05-15 | ||||||||||
| 2023-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $8.98M derived: sum of 2 quarters · filed 2025-03-31 | $8.98M derived: sum of 3 quarters · filed 2025-03-31 | $8.98M 10-K · filed 2025-03-31 | ||||||||||
| 2023-09-30 | $5.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.38M derived: sum of 2 quarters · filed 2024-11-12 | $5.38M 10-Q · filed 2024-11-12 | $5.36M derived: sum of 4 quarters · filed 2024-11-12 | ||||||||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | -$12.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.32M derived: sum of 4 quarters · filed 2024-08-13 | ||||||||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | -$12.00K derived: sum of 2 quarters · filed 2024-05-10 | $1.32M derived: sum of 3 quarters · filed 2024-05-10 | $2.90M derived: sum of 4 quarters · filed 2024-05-10 | ||||||||||
| 2022-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.32M derived: sum of 2 quarters · filed 2024-03-08 | $2.90M derived: sum of 3 quarters · filed 2024-03-08 | $3.79M 10-K · filed 2024-03-08 | ||||||||||
| 2022-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.92M derived: sum of 2 quarters · filed 2023-11-13 | $3.80M 10-Q · filed 2023-11-13 | $11.83M derived: sum of 4 quarters · filed 2023-11-13 | ||||||||||
| 2022-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $2.47M 10-Q · filed 2023-08-11 | $10.50M derived: sum of 3 quarters · filed 2023-08-11 | $12.10M derived: sum of 4 quarters · filed 2023-08-11 | ||||||||||
| 2022-03-31 | $882.00K 10-Q · filed 2023-05-15 | $8.91M derived: sum of 2 quarters · filed 2023-05-15 | $10.51M derived: sum of 3 quarters · filed 2023-05-15 | $28.48M derived: sum of 4 quarters · filed 2023-05-15 | ||||||||||
| 2021-12-31 | $8.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $9.63M derived: sum of 2 quarters · filed 2023-03-30 | $27.59M derived: sum of 3 quarters · filed 2023-03-30 | $27.61M 10-K · filed 2023-03-30 | ||||||||||
| 2021-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $19.57M derived: sum of 2 quarters · filed 2022-11-04 | $19.57M 10-Q · filed 2022-11-04 | $39.07M derived: sum of 4 quarters · filed 2022-11-04 | ||||||||||
| 2021-06-30 | $17.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $17.98M 10-Q · filed 2022-08-12 | $37.47M derived: sum of 3 quarters · filed 2022-08-12 | $38.40M derived: sum of 4 quarters · filed 2022-08-12 | ||||||||||
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-13 | $19.51M derived: sum of 2 quarters · filed 2022-05-13 | $20.43M derived: sum of 3 quarters · filed 2022-05-13 | $20.68M derived: sum of 4 quarters · filed 2022-05-13 | ||||||||||
| 2020-12-31 | $19.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $20.42M derived: sum of 2 quarters · filed 2022-03-24 | $20.67M derived: sum of 3 quarters · filed 2022-03-24 | $21.12M 10-K · filed 2022-03-24 | ||||||||||
| 2020-09-30 | $924.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.18M derived: sum of 2 quarters · filed 2021-11-12 | $1.62M 10-Q · filed 2021-11-12 | -$1.33M derived: sum of 4 quarters · filed 2021-11-12 | ||||||||||
| 2020-06-30 | $252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $700.00K 10-Q · filed 2021-08-12 | -$2.25M derived: sum of 3 quarters · filed 2021-08-12 | -$2.25M derived: sum of 4 quarters · filed 2021-08-12 | ||||||||||
| 2020-03-31 | $448.00K 10-Q · filed 2021-05-07 | -$2.50M derived: sum of 2 quarters · filed 2021-05-07 | -$2.50M derived: sum of 3 quarters · filed 2021-05-07 | -$2.50M derived: sum of 4 quarters · filed 2021-05-07 | ||||||||||
| 2019-12-31 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$2.95M derived: sum of 2 quarters · filed 2021-03-11 | -$2.95M derived: sum of 3 quarters · filed 2021-03-11 | $4.70M 10-K · filed 2021-03-11 | $7.65M 10-K · filed 2020-02-21 | |||||||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $7.65M 10-Q · filed 2020-10-29 | |||||||||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $7.65M 10-Q · filed 2020-08-14 | ||||||||||||
| 2019-03-31 | $7.65M 10-Q · filed 2020-05-07 | |||||||||||||
| 2018-12-31 | $6.77M 10-K · filed 2020-02-21 | |||||||||||||
| 2017-12-31 | $7.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $7.33M derived: sum of 2 quarters · filed 2019-03-07 | $19.75M derived: sum of 3 quarters · filed 2019-03-07 | $22.11M 10-K · filed 2019-03-07 | ||||||||||
| 2017-09-30 | -$113.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $12.31M derived: sum of 2 quarters · filed 2018-11-02 | $14.67M 10-Q · filed 2018-11-02 | |||||||||||
| 2017-06-30 | $12.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $14.79M 10-Q · filed 2018-08-03 | ||||||||||||
| 2017-03-31 | $2.37M 10-Q · filed 2018-05-04 | |||||||||||||
| 2014-06-30 | $907.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | $24.84M 10-Q · filed 2014-08-13 | $30.60M derived: sum of 3 quarters · filed 2014-08-13 | $37.15M derived: sum of 4 quarters · filed 2014-08-13 | ||||||||||
| 2014-03-31 | $23.93M 10-Q · filed 2014-05-14 | $29.69M derived: sum of 2 quarters · filed 2014-05-14 | $36.25M derived: sum of 3 quarters · filed 2014-05-14 | $36.27M derived: sum of 4 quarters · filed 2014-05-14 | $110.51M 10-Q · filed 2014-05-14 | |||||||||
| 2013-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $12.31M derived: sum of 2 quarters · filed 2014-03-21 | $12.34M derived: sum of 3 quarters · filed 2014-03-21 | $12.34M 10-K · filed 2014-03-21 | $86.57M 10-K · filed 2014-03-21 | |||||||||
| 2013-09-30 | $6.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $6.58M derived: sum of 2 quarters · filed 2013-11-13 | $6.58M 10-Q · filed 2013-11-13 | $14.64M derived: sum of 4 quarters · filed 2013-11-13 | $80.82M 10-Q · filed 2013-11-13 | |||||||||
| 2013-06-30 | $26.74K derived: 10-Q 147 month − 10-Q 144 month · filed 2013-08-12 | $26.74K 10-Q · filed 2014-08-13 | $8.08M derived: sum of 3 quarters · filed 2013-08-12 | $8.08M derived: sum of 4 quarters · filed 2013-08-12 | $74.26M 10-Q · filed 2013-08-12 | |||||||||
| 2013-03-31 | $0.00 derived: 10-Q 144 month − 10-K 141 month · filed 2013-05-09 | $8.05M derived: sum of 2 quarters · filed 2013-05-09 | $8.05M derived: sum of 3 quarters · filed 2013-05-09 | $8.05M derived: sum of 4 quarters · filed 2013-05-09 | $74.23M 10-Q · filed 2013-05-09 | |||||||||
| 2012-12-31 | $8.05M derived: 10-K 141 month − 10-Q 138 month · filed 2013-03-22 | $8.05M derived: sum of 2 quarters · filed 2013-03-22 | $8.05M derived: sum of 3 quarters · filed 2013-03-22 | $8.05M 10-K · filed 2014-03-21 | $74.23M 10-K · filed 2013-03-22 | |||||||||
| 2012-09-30 | $0.00 derived: 10-Q 138 month − 10-Q 135 month · filed 2012-11-08 | $0.00 derived: sum of 2 quarters · filed 2012-11-08 | $0.00 derived: sum of 3 quarters · filed 2012-11-08 | $19.20K derived: sum of 4 quarters · filed 2013-03-22 | $66.18M 10-Q · filed 2012-11-08 | |||||||||
| 2012-06-30 | $0.00 derived: 10-Q 135 month − 10-Q 132 month · filed 2012-08-08 | $0.00 derived: sum of 2 quarters · filed 2012-08-08 | $19.20K derived: sum of 3 quarters · filed 2013-03-22 | $41.24K derived: sum of 4 quarters · filed 2013-03-22 | $66.18M 10-Q · filed 2012-08-08 | |||||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-09 | $19.20K derived: sum of 2 quarters · filed 2013-03-22 | $41.24K derived: sum of 3 quarters · filed 2013-03-22 | $41.24K derived: sum of 4 quarters · filed 2013-03-22 | $66.18M 10-Q · filed 2012-05-09 | |||||||||
| 2011-12-31 | $19.20K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | $41.24K derived: sum of 2 quarters · filed 2013-03-22 | $41.24K derived: sum of 3 quarters · filed 2013-03-22 | $13.60M 10-K · filed 2013-03-22 | ||||||||||
| 2011-09-30 | $22.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $22.04K derived: sum of 2 quarters · filed 2012-11-08 | $13.58M 10-Q · filed 2012-11-08 | $13.58M derived: sum of 4 quarters · filed 2012-11-08 | ||||||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $13.56M 10-Q · filed 2012-08-08 | $13.56M derived: sum of 3 quarters · filed 2012-08-08 | $13.56M derived: sum of 4 quarters · filed 2012-08-08 | ||||||||||
| 2011-03-31 | $13.56M 10-Q · filed 2012-05-09 | $13.56M derived: sum of 2 quarters · filed 2012-05-09 | $13.56M derived: sum of 3 quarters · filed 2012-05-09 | |||||||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16 | $0.00 derived: sum of 2 quarters · filed 2012-03-16 | $12.69M 10-K · filed 2012-03-16 | |||||||||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $12.69M 10-Q · filed 2011-11-09 | ||||||||||||
| 2010-06-30 | $12.69M 10-Q · filed 2011-08-09 | |||||||||||||
| 2009-12-31 | $10.73M 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |